Surface Engineered Nanoparticles for MRI Contrast

用于 MRI 对比的表面工程纳米颗粒

• 批准号: 7053399
• 负责人: David BRENT MACQUEEN
• 金额: $ 26.59万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-15 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7053399
• 关键词: aluminum; antigen antibody reaction; binding sites; bioengineering /biomedical engineering; bioimaging /biomedical imaging; contrast media; cytotoxicity; gadolinium; immunoconjugates; infrared spectrometry; laboratory rat; magnetic resonance imaging; nuclear magnetic resonance spectroscopy; particle; pharmacokinetics; surface coating; technology /technique development

DESCRIPTION (provided by applicant): The long-term goal of this research is to develop a multifunctional nanoparticulate contrast agent for cancer imaging that, through proper surface engineering, affords site specificity coupled with both diagnostic and therapeutic capabilities in a single package. The nanoparticulate material that will be investigated is one that the PI has employed in the development of advanced ceramics and inorganicorganic hybrid composites. The ability to surface engineer the elemental composition of the ceramic nanoparticle and the ability to effectively control the organic functionalities at the surface of the particulates have been established. What has not been established is the effect that process conditions have upon the physical properties relevant to their use as contrast agents, and their behavior in animal models. The preliminary results that have been obtained with these materials, r1 > 30 mM(-1)s(-1), with no effort to optimize the composition, clearly establishes that the GadAL materials warrant the proposed investigation. The goal of this R21 application is to establish benchmark values for the physical properties of a nanoparticle based system with respect to stability, relaxivity, and particle size for use as a magnetic resonance imaging (MRI) contrast enhancement agent. The benchmark properties will be used to determine if the nanoparticulate materials are suitable for further study. The interdisciplinary project team we have assembled for this R21 research effort, SRI's Physical Sciences, Biopharmaceutical, Policy Divisions and from Alerion, Inc., who will be a subcontractor on this application, have the capability and expertise necessary to perform the materials synthesis and analysis for optimization of the nanoparticulate contrast agent performance, conduct the toxicological and pharmacokinetics analysis, and begin the process of agent development should the results of this application warrant.

描述（由申请人提供）： 这项研究的长期目标是为癌症成像开发多功能的纳米构造对比剂，该对比剂通过适当的表面工程提供了现场特异性，并在单个包装中提供了诊断和治疗能力。 PI在晚期陶瓷和无机杂化复合材料的开发中使用的纳米构造物质是一种PI的发展。已经建立了陶瓷纳米颗粒的元素组成以及有效控制颗粒表面上有机功能的能力。尚未确定的是过程条件对与它们用作对比剂的使用以及它们在动物模型中的行为相关的物理特性的影响。这些材料（R1> 30 mm（-1）s（-1）获得的初步结果，没有努力优化组合物，清楚地表明，加达尔材料值得拟议的研究。该R21应用的目的是建立基于纳米颗粒系统的物理性质的基准值，以用作磁共振成像（MRI）对比度增强剂的稳定性，松弛性和粒径。基准特性将用于确定纳米构造材料是否适合进一步研究。我们为R21研究工作组装的跨学科项目团队，SRI的身体科学，生物制药，政策分歧，以及来自Alerion，Inc。，他们将在此应用中成为分包商，具有对进行材料合成的材料综合和分析的功能和专业知识，以开发纳米疗法及其对构成毒品的毒性及其分析，并进行毒性及其毒性及其分析，并进行毒性及其毒性及其分析。此申请的保证。